Combo Products Should Be More Than The Sum Of Their Parts – Biotech Execs
This article was originally published in The Gray Sheet
Executive Summary
Developers of drug/device combination products looking for investor support must prove the technology is safer or more effective than stand-alone alternatives, and not merely more convenient, according to participants at the Nov. 10-11 Biotech 2008 meeting in Philadelphia